In vivo 'purging' of residual disease in CLL with Campath-1H.

In vivo 'purging' of residual disease in CLL with Campath-1H.

We assessed the role of human CD52 antibody (Campath-1H) in six patients with chronic lymphocytic leukaemia (CLL) treated to maximal response with purine analogues (fludarabine/deoxycoformycin) in whom persistent leukaemic infiltration of blood and bone marrow had precluded autologous stem cell tran...

Descripció completa

Dades bibliogràfiques
Autors principals:	Dyer, M, Kelsey, S, Mackay, H, Emmett, E, Thornton, P, Hale, G, Waldmann, H, Newland, A, Catovsky, D
Format:	Journal article
Idioma:	English
Publicat:	1997

Ítems similars

Specificity of monoclonal antibody Campath-1.
per: Hale, G, et al.
Publicat: (1988)

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
per: Dyer, M, et al.
Publicat: (1989)

The CAMPATH-1 antigen (CDw52).
per: Hale, G, et al.
Publicat: (1990)

CAMPATH-1H in inflammatory arthritis.
per: Watts, R, et al.
Publicat: (1993)

CAMPATH: from concept to clinic.
per: Waldmann, H, et al.
Publicat: (2005)

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
per: Lundin, J, et al.
Publicat: (2001)

Campath-1H therapy in refractory ocular inflammatory disease.
per: Dick, A, et al.
Publicat: (2000)

EFFECTS OF MONOCLONAL-ANTIBODIES OF THE CAMPATH SERIES INVIVO - REQUIREMENTS FOR EFFECTIVE ANTIBODY THERAPY
per: Dyer, M, et al.
Publicat: (1988)

ISOTYPE VARIANTS OF CAMPATH-1 ANTIBODY - REQUIREMENTS FOR EFFECTIVE ANTIBODY ACTION INVIVO
per: Dyer, M, et al.
Publicat: (1989)

Availability of Campath-1 antibodies for bone marrow transplantation.
per: Hale, G, et al.
Publicat: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
per: Hale, G, et al.
Publicat: (1994)

REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
per: Dyer, M, et al.
Publicat: (1990)

A personal history of the CAMPATH-1H antibody.
per: Waldmann, H
Publicat: (2002)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
per: Watts, R, et al.
Publicat: (1992)

Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with CAMPATH-1H.
per: Buggins, A, et al.
Publicat: (2001)

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
per: Killick, S, et al.
Publicat: (1997)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
per: Hale, G, et al.
Publicat: (2002)

Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.
per: Hale, G, et al.
Publicat: (1988)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
per: Hale, G, et al.
Publicat: (1988)

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
per: Isaacs, J, et al.
Publicat: (1996)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
per: Williams, R, et al.
Publicat: (2000)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
per: Fibbe, W, et al.
Publicat: (1993)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
per: Chakrabarti, S, et al.
Publicat: (2004)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
per: Hale, G, et al.
Publicat: (1996)

The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
per: Willis, F, et al.
Publicat: (2001)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
per: Waldmann, H, et al.
Publicat: (1987)

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
per: Lundin, J, et al.
Publicat: (2002)

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
per: Kottaridis, P, et al.
Publicat: (2000)

T-cell depletion of bone marrow grafts with Campath 1 ex vivo prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation
per: Novitzky, N, et al.
Publicat: (1997)

Ex vivo T-cell depletion of bone marrow grafts with campath 1 prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation.
per: Novitzky, N, et al.
Publicat: (1997)

CAMPATH-1 FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT-REJECTION - SUMMARY OF RESULTS FROM A MULTI-CENTRE STUDY
per: Hale, G, et al.
Publicat: (1988)

T-CELL DEPLETION BY EXPOSURE TO CAMPATH-1G IN-VITRO PREVENTS GRAFT-VERSUS-HOST DISEASE
per: Jacobs, P, et al.
Publicat: (1994)

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.
per: Isaacs, J, et al.
Publicat: (1995)

CAMPATH-IH in multiple sclerosis.
per: Moreau, T, et al.
Publicat: (1996)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
per: Lim, S, et al.
Publicat: (1993)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
per: Novitzky, N, et al.
Publicat: (2004)

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
per: Kottaridis, P, et al.
Publicat: (2001)

CAMPATH-1 antibodies in stem-cell transplantation.
per: Hale, G, et al.
Publicat: (2001)

Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect.
per: Novitzky, N, et al.
Publicat: (1999)

In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation.
per: Willemze, R, et al.
Publicat: (1992)